Field Alert Reports: Three Working Days, and Most Firms Miss It
A Field Alert Report (FAR) is required under 21 CFR 314.81(b)(1) when an NDA or ANDA holder receives information about a distributed drug product that suggests a problem with its identity, strength, quality, purity or potency.
The clock is three working days from receipt of the information. Not from confirming it, and not from completing an investigation.
What triggers one
Mislabelling or product mix-up. Any information concerning mislabelling, including a wrong label, a mix-up of products, or labelling that could cause a patient to take the wrong thing.
Bacteriological contamination, or any significant chemical, physical or other change or deterioration in the distributed product.
Failure of a distributed batch to meet its specification, including a stability failure at any timepoint.
The last one catches people. A stability sample from a distributed batch that falls out of specification is a field alert, even though nothing on the market has visibly failed.
What does not trigger one
- A specification failure in a batch that was never distributed. Investigate it, but it is not a field alert.
- A single unconfirmed complaint with no supporting information suggesting an actual product problem.
- A problem with a clinical trial supply rather than a marketed product.
The three-day clock is the hard part
Three working days is not enough time to investigate. That is deliberate: FDA wants to know early, not correctly.
So the FAR is initial and explicitly incomplete. You state what you know, what you are doing, and then submit follow-ups as the investigation proceeds, including a final report when it concludes.
Firms miss the deadline in a predictable way: the information arrives in quality as a complaint or an OOS result, the investigation begins, and nobody asks the separate question of whether it is also reportable until the investigation is well advanced. By then the three days have gone.
The fix is procedural rather than analytical. Whoever receives the information has to make a reportability call immediately, in parallel with the investigation, not after it.
Over-reporting is the safer error here
Unlike a reporting category decision, where over-reporting costs real time, a field alert submitted on information that turns out to be nothing costs very little. A missed one is a violation, and it appears in warning letters.
Where the call is genuinely unclear, file and follow up.
Frequently asked questions
What is a field alert report?
A report to FDA, required within three working days, about information concerning a distributed drug product that may reflect a problem with its identity, strength, quality, purity or potency.
Which regulation requires it?
21 CFR 314.81(b)(1), applying to NDA and ANDA holders.
Does a stability failure require a FAR?
If the batch was distributed, yes. A failure in a batch never distributed does not.
What if the investigation is not finished?
File anyway. The initial report is expected to be incomplete, with follow-ups as the investigation proceeds.
Do I need one for a clinical trial supply?
No. FARs concern marketed products under an approved application.
Is a FAR the same as a recall?
No. A FAR is a report. A [recall](/tools/recall-search) is a removal or correction, and one may follow the other.